Sun, Huikai et al. published their research in Journal of Medicinal Chemistry in 2021 | CAS: 367501-08-4

4-(2,4-Difluorophenoxy)piperidine (cas: 367501-08-4) belongs to piperidine derivatives. The piperidine ring can be found not only in more than half of the currently known structures of alkaloids, but also in many natural or synthetic compounds with interesting biological activities. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Computed Properties of C11H13F2NO

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate was written by Sun, Huikai;Monenschein, Holger;Schiffer, Hans H.;Reichard, Holly A.;Kikuchi, Shota;Hopkins, Maria;Macklin, Todd K.;Hitchcock, Stephen;Adams, Mark;Green, Jason;Brown, Jason;Murphy, Sean T.;Kaushal, Nidhi;Collia, Deanna R.;Moore, Steve;Ray, William J.;Carlton, Mark Beresford Lewis;Brice, Nicola L.. And the article was included in Journal of Medicinal Chemistry in 2021.Computed Properties of C11H13F2NO This article mentions the following:

Parkinson’s disease (PD) is a chronic and progressive movement disorder with the urgent unmet need for efficient symptomatic therapies with fewer side effects. GPR6 is an orphan G-protein coupled receptor (GPCR) with highly restricted expression in dopamine receptor D2-type medium spiny neurons (MSNs) of the indirect pathway, a striatal brain circuit which shows aberrant hyperactivity in PD patients. Potent and selective GPR6 inverse agonists (IAG) were developed starting from a low-potency screening hit (EC50 = 43μM). Herein, we describe the multiple parameter optimization that led to the discovery of multiple nanomolar potent and selective GPR6 IAG, including our clin. compound CVN424 (I). GPR6 IAG reversed haloperidol-induced catalepsy in rats and restored mobility in the bilateral 6-OHDA-lesioned rat PD model demonstrating that inhibition of GPR6 activity in vivo normalizes activity in basal ganglia circuitry and motor behavior. CVN424 is currently in clin. development to treat motor symptoms in Parkinson’s disease. In the experiment, the researchers used many compounds, for example, 4-(2,4-Difluorophenoxy)piperidine (cas: 367501-08-4Computed Properties of C11H13F2NO).

4-(2,4-Difluorophenoxy)piperidine (cas: 367501-08-4) belongs to piperidine derivatives. The piperidine ring can be found not only in more than half of the currently known structures of alkaloids, but also in many natural or synthetic compounds with interesting biological activities. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Computed Properties of C11H13F2NO

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem